What's Happening?
Calidar, Inc. has completed enrollment in its first-in-human clinical study of the 4D Mammography system, a next-generation imaging platform aimed at improving breast cancer diagnostics. Conducted in collaboration with Baptist Health Hardin, the study enrolled
61 patients and aims to evaluate the system's ability to distinguish between healthy and cancerous breast tissue. The 4D Mammography system uses X-ray diffraction to measure molecular-level signals within breast tissue, offering a new dimension of diagnostic clarity. Data analysis is ongoing, and results are expected to be published in a peer-reviewed paper in the second half of 2026.
Why It's Important?
This development is crucial as it represents a potential breakthrough in breast cancer diagnostics, a field where current methods often lead to unnecessary biopsies and delayed diagnoses. The 4D Mammography system could significantly reduce healthcare costs and improve diagnostic accuracy, benefiting both patients and healthcare providers. If successful, this technology could lead to earlier detection of breast cancer, improving patient outcomes and potentially saving lives. The study's completion marks a significant step towards obtaining FDA approval, which would allow for broader clinical use.
What's Next?
Following the completion of data analysis, Calidar plans to initiate a Series A funding round to support a multi-site pivotal study. This study will be crucial for obtaining FDA approval for the 4D Mammography system. If approved, the technology could be commercialized, leading to widespread adoption in clinical settings. The results of the ongoing analysis and the subsequent pivotal study will be closely watched by stakeholders in the healthcare and medical technology sectors.
